Johnson Sun 孙 凤 强 公 司 报 告 : 国 药 控 股 (01099 HK) johnson.sun@gtjas.com.hk
|
|
- Alexandra Thompson
- 8 years ago
- Views:
Transcription
1 GTJA Research 国 泰 君 安 研 究 Company Report: Sinopharm (01099 HK) Johnson Sun 孙 凤 强 公 司 报 告 : 国 药 控 股 (01099 HK) johnson.sun@gtjas.com.hk 16 April 2013 Dilemma of Fast Growth or Healthy Operating Cash Flow, Sell 高 增 长 和 经 营 现 金 流 的 两 难 抉 择, 卖 出 2012 results are very disappointing with 1) 24.2% YoY net profit growth, after removing the one-off gains from PPE disposal, 2) -RMB4.1bn operating cash flow after removing influences of A/R and A/P factoring (reported: RMB4.0 bn). Our A/R calculation model indicates actual A/R days increased from 97.4 days to days in 2012 (reported: 86 days). Share placement in Mar is as per our expectation in our previous reports. Growth is slowing down. M&A-driven growth is slowing down due to 1) fewer acquisitions in 2012, and 2) Completion of VAM for most 2011 acquisitions. Industry growth is also slowing down. With 22.9% of the total A/R overdue and worsening operating cash flows, Sinopharm faces a dilemma in revenue expansion and healthy operating cash flow. We may have over-estimated the role of pharmaceutical distributors in the supply chain. Re-evaluation of the business model and pharmaceutical supply chain could explain and estimate the trend of 1) pressures in gross margin, 2) increasing A/R days and stable A/P days, and 3) fiercer competition among nation-wide distributors and provincial distributors. Our EPS estimates are 12%, 18% and 20% lower than consensus. We think the market has largely under-estimated operating cash flow pressures of Sinopharm caused by revenue expansion and under-estimated the heavy financial costs, especially for A/R factorings. Maintain Sell and cut TP to HK$17.60, reflecting 15.7x 2013 PE and 1.3x PEG. Short-sell is not recommended 业 绩 令 人 失 望 :1) 扣 除 处 置 资 产 获 得 的 一 次 性 收 益, 公 司 净 利 润 同 比 增 长 24.2%, 2) 扣 除 应 收 账 款 和 应 付 账 款 保 理, 公 司 经 营 现 金 流 出 RMB41 亿 元 ( 未 扣 除 前 : 经 营 现 金 流 入 40 亿 元 ) 我 们 对 应 收 账 款 保 理 的 计 算 显 示, 公 司 实 际 应 收 账 款 天 数 从 2011 年 的 97.4 天 上 升 至 2012 年 的 天 ( 年 报 :86 天 ) 公 司 2013 年 3 月 配 股, 符 合 我 们 之 前 的 预 期 增 速 放 缓 并 购 推 动 的 增 速 放 缓, 因 为 1)2012 年 的 收 购 减 少,2)2011 年 收 购 的 企 业 对 赌 协 议 基 本 结 束 行 业 增 长 也 放 缓 公 司 22.9% 的 应 收 账 款 已 经 过 期, 现 金 流 将 会 更 差 公 司 面 临 收 入 扩 张 还 是 健 康 现 金 流 的 两 难 抉 择 我 们 可 能 高 估 了 医 药 流 通 企 业 在 供 应 链 中 的 角 色 对 流 通 企 业 商 业 模 式 和 供 应 链 的 重 新 评 估, 可 能 会 更 好 的 解 释 及 预 测 1) 毛 利 率 下 跌 的 压 力,2) 应 收 账 款 天 数 不 断 延 长, 但 应 付 账 款 天 数 基 本 不 变,3) 全 国 性 及 省 级 分 销 企 业 之 前 加 剧 的 竞 争 我 们 对 公 司 年 的 EPS 预 测 分 别 低 于 市 场 预 期 12% 18% 和 20% 我 们 认 为 市 场 可 能 大 幅 低 估 了 在 收 入 增 长 时 其 现 金 流 的 压 力, 及 低 估 了 主 要 由 于 应 收 账 款 保 理 带 来 的 财 务 费 用 压 力 维 持 卖 出 评 级, 下 调 目 标 价 至 港 元, 相 当 于 15.7x 2013 PE 和 1.3x PEG. 但 不 建 议 做 空 Rating: Sell Maintained 评 级 : 卖 出 ( 维 持 ) 6-18m TP 目 标 价 : HK$17.60 Revised from 原 目 标 价 HK$21.60 Share price 股 价 : Stock performance 股 价 表 现 (10.0) (20.0) % of return HK$ (30.0) Apr-12 Jul-12 Oct-12 Jan-13 Apr-13 Change in Share Price 股 价 变 动 HSI Index Sinopharm 1 M 1 个 月 3 M 3 个 月 1 Y 1 年 Abs. % 绝 对 变 动 % (4.6) (4.1) 20.1 Rel. % to HS index 相 对 恒 指 变 动 % (0.8) Avg. share price(hk$) 平 均 股 价 ( 港 元 ) Source: Bloomberg, Guotai Junan International Year End Turnover Net Profit EPS EPS PER BPS PBR DPS Yield ROE 年 结 收 入 股 东 净 利 每 股 净 利 每 股 净 利 变 动 市 盈 率 每 股 净 资 产 市 净 率 每 股 股 息 股 息 率 净 资 产 收 益 率 12/31 (RMB m) (RMB m) (RMB) ( %) (x) (RMB) (x) (RMB) (%) (%) 2011A 102,225 1, A 135,787 1, F 163,663 2, F 200,781 2, F 244,509 3, Shares in issue (m) 总 股 数 (m) 2,568.3 Major shareholder 大 股 东 CNPGC 33.4% Market cap. (HK$ m) 市 值 (HK$ m) 63,565.3 Free float (%) 自 由 流 通 比 率 (%) month average vol. 3 个 月 平 均 成 交 股 数 ( 000) 4,573.3 FY13 Net gearing (%) FY13 净 负 债 / 股 东 资 金 (%) Weeks high/low (HK$) 52 周 高 / 低 / Source..the Company, Guotai Junan International. See the last page for disclaimer Page 1 of 8
2 2012 Results Review Revenue grew by 32.8% YoY to RMB135.7 bn in The growth is consisted of 1)4.6ppt (~RMB6.2 bn) from acquisitions in 2012, 2)9ppt (~RMB27.7 bn) from the growth of 2011 s acquired business, 3)19.2ppt from the existed business since Organic growth is slowing down. Organic growth of the Company was 19.2% YoY in 2012, slower than 21%-22% YoY in (Note: in order to eliminating influences of consolidation timing, the 2012 organic growth refers to the growth of existing business since 2011 without the acquisitions of 2011 and 2012, and the 2011 organic growth refers to the growth of existing business since 2010 without the acquisitions of 2010 and 2011). EBIT grew by 33.7% YoY, slightly improved EBIT margin from 3.56% to 3.58%, due to 1) erosion of gross margin, 2) reduced SG&A ratios thanks to business scale expansion. Recurring net profit grew by 24.2% YoY to RMB1,687 mn, if excluding the non-recurring gains (RMB287 mn in 2012 and RMB202 mn in 2011, mainly from gains of PPE disposals). Net profit grew by 26.5% YoY to RMB1.97 bn. Net profit growth was greatly affected by the 56% YoY increased financial costs, slightly affected by the 31.4% YoY increased minority shareholders interest. Significant improvement of operating cash flows by accounting techniques. In 2012, operating cash flow of the Company was RMB4.0 bn, 3 times higher than We attribute the improvement to 2 accounting techniques: 1) A/R factoring (including note receivables factoring, +3.2 bn in operating cash flow) and 2) A/P factoring (+5.0 bn in operating cash flow). Excluding the above 2 accounting techniques, actual operating cash flow of the Company was estimated to be -RMB4.1bn. A/R factoring and financial costs. Account receivables and note receivables factoring are used widely by the Company because 1) it helps improve operating cash flows and relieves pressures of working capital, 2) according to the management, note factoring rate is sometimes lower than short borrowing interest rate. Based on assumption of average factoring rate of 6.0% in 2012, we estimated around RMB22.34 bn receivables were factored, accounting for 16.5% of its total revenue in the year. Actual A/R days increased from 97.4 days in 2011 to days in 2012, according to our A/R factoring calculation model. It is much longer than the reported A/R days of 79.2 in 2011 and 86.0 in 2012, respectively. According to our estimates, one-day increase in A/R days in 2012 need ~RMB750 mn increase in working capital, and as a result, the Company increased its working capital by RMB4,125 mn due to increase in A/R days. Table-1: A/R factoring & financial costs calculations (RMB mn) RMB mn 2010A 2011A 2012A 2013F 2014F 2014F Financial costs from discount receivables (reported) ,192 Average factoring rate (assumption) 7.0% 7.0% 6.0% 6.0% 6.0% 6.0% Discounted receivables in the year 12,568 19,146 22,340 31,181 43,425 60,438 Discounted receivables to revenue ratio 18.2% 18.7% 16.5% 18.5% 21.0% 24.0% Actual A/R days Reported A/R days Sources: the Company, Guotai Junan International. Note: our A/R factoring calculation model is available upon request. A/P factoring of RMB4,962 mn: pressure or new choice? A/P factoring, or A/P financing program is a new banking service in 2012, according to the management. Certain banks repaid A/P on behalf of the Company, with an equivalent sum See the last page for disclaimer Page 2 of 8
3 drawn as borrowings. In 2012, the Company totaled A/P factoring of RMB4,962 mn, and as a result, the RMB4,962 mn flow out was accounted as financial cash flow, instead of operating cash flow. We think this a new technique for the Company to present a less ugly operating cash flow, and it may reflect the great payment pressures. Essentially, we think the Company could not meet the payment date and has to ask for short credit borrowings for some bills, and it is different from A/R factoring, because A/R factoring is a kind of borrowing with pledged A/R (with lower interest rate). Conclusion: we think 2012 results are very disappointing with 1) 24.2% YoY net profit growth, after removing the one-off gains from PPE disposal, 2) -RMB4.1bn operating cash flow after removing influences of A/R and A/P factoring. We are more worried about its growth slowdown and worsening operating cash flow. Expectations with Worries M&A-driven growth is slowing down. Although revenue growth contribution of 2012 s M&A was only 4.6ppt, its growth from 2011 s acquisition was 9.0ppt, mainly due to 1) incentive to the newly acquired subsidiaries with the Value-Adjustment-Mechanism (VAM, 对 赌 协 议 ), 2) consolidation timing of these acquisitions. In 2013, contributions from acquisitions will be much less due to 1) few acquisitions in 2012, and 2) finish of VAM for most 2011 acquisitions. Industry growth is also slowing down. In March 2013, China s medicine sales grew by only 19.1% YoY, much lower than the 24.0% YoY growth of Jan-Feb 2013, the 29.5% YoY growth of 2012, the 29.0% CAGR of , or the 23.1% CAGR of The slowdown is due to 1) government s medical insurance cost control, 2) destocking of distributors with expectations of price drug cut in future tendering. We expect the slowdown of industry growth to last for Figure-1: Medicine sales growth in China 40.0% 30.0% 20.0% 10.0% 0.0% 0.8% 14.3% 6.6% 22.1% 9.7% 12.2% 10.4% 5.2% 19.2% 7.3% 29.7% 32.9% 29.5% 25.1% 24.7% 24.0% 19.1% 14.8% -10.0% -20.0% -18.2% -30.0% Source: National Bureau of Statistics of China, Guotai Junan International Operating cash flow is worsening. Based on the 2012 revenue, a 1-day increase in A/R days will need RMB750 mn more working capital, and a 1 bn growth in revenue will need RMB200 mn more working capital. About 22.9% of the total A/R was over-due. In 2012 year end, the Company had RMB8.6 bn A/R that were past due, accounting for 22.9% of its total A/R. As listed in table-2, 95.1%, 99.1% and 63.2% of it s A/R aged 3-6 months, 6-12 months and over 12 months was past due. Although these over-due bills are still collectable and not considered impaired because most of them are from public hospitals, we are concerned of the cash flow situation of these clients. See the last page for disclaimer Page 3 of 8
4 Table-2 : Past-due A/R ratio for different groups of A/R of Sinopharm months 94.3% 95.2% 95.1% 6-12 months 88.9% 98.3% 99.1% over 12 months 24.6% 44.8% 63.2% Total 17.5% 22.7% 22.9% Sources: the Company, Guotai Junan International. A/R days is expected to increase from days in 2012 to 110 days in 2013, according to our estimates. The increase is mainly due to worsening cash flow situation of hospitals. The increase will make Sinopharm need ~6 bn more working capital (as operating cash outflow). Dilemma in expansion and cash flow problems. Sinopharm is given the mission to seize more market shares in pharmaceutical distribution industry, in order to meet the requirement of ongoing healthcare reform of China. However, such expansion needs great working capitals. Our 20.5% YoY top-line growth projection in 2013 makes it need ~5.6bn more working capitals, according to our estimates. As a result, we think it may have to slow down revenue expansion mainly due to cash flow stress. Continuous financing is needed. Sinopharm finances by 1) short borrowing (including A/P factoring), 2) bond issuance, 3) A/R factoring, and 4) share placement. As we expected in the report on Nov 2012 and in the report of Sep 2012, it did placed new share for HK$4 bn in Mar Financial costs will increase largely (by 21% YoY and 33% YoY in 2013 and 2014) and erode its profit, and the placement will dilute its EPS. Business Model and Supply Chain Re-evaluation Pharmaceutical distributors are simply transporters? In pharmaceutical supply chain, hospitals are not the ultimate end-users, but they decide which drugs to use. Manufacturers try to promote their pharmaceutical products in hospitals, and distributors simply transport these products to hospitals. Although distributors also provide value-added services including bills collection, we think their core competence is still help to reduce transportation costs for their large transportation scales. Without controls on the manufacturing and sales of the products they carry, pharmaceutical distributors may be more specialized transporters (It is different from pharmaceutical promoters such as CMS (00867 HK)). Pharmaceutical distributors provide indistinctive products? The products of pharmaceutical distributors are transportation services and some value-added services along the transportation, instead of the medicine products which are provided by manufacturers. Simply, we think the products are indistinctive among these large distributors, including Sinopharm, Shanghai Pharm (02607 HK), CR Pharm, and other provincial competitors. Limited economies of scale? Different from telecommunication networks owned by China Mobile, large nation-wide pharmaceutical distributors may be not more competitive than provincial distributors in certain provinces. After the construction of distribution centers of provincial pharmaceutical distributors, competition may be fiercer and large distributors may face margin erosions. We think we may have over-estimated value of pharmaceutical distributors in the supply chain. Re-evaluation of the business model and pharmaceutical supply chain could explain and estimate the trend of 1) pressures in gross margin, 2) increasing A/R days and stable A/P days, and 3) fiercer competitions among nation-wide distributors and provincial distributors. (This is our primary viewpoint for discussion instead of conclusion.) See the last page for disclaimer Page 4 of 8
5 Earnings and investment suggestions Cut ESP estimates by 12% to RMB0.883 for 2013, and by 22% to RMB1.012 for 2014, due to 1) revised-down top-line growth estimates, 2) dilution of new share placement. We introduce 2015 EPS estimates of RMB Our estimates reflect 7.5%/14.6%/17.3% YoY growth in , much lower than the CAGR of 24.1% in , and EPS CAGR is estimated to be 15.7%. Our EPS estimates are 12%, 18% and 20% lower than consensus, respectively. We think the market has underestimated operating cash flow pressures of Sinopharm caused by revenue expansion and underestimated the heavy financial costs, especially for A/R factorings. Maintain Sell and cut TP to HK$17.60 for Sinopharm, reflecting 15.7x 2013PE and 1.3x PEG. We had expected its 2012 results to be very disappointing due to 1) slowdown growth of newly acquired subsidiaries after VAM finished, and 2) bad operating cash flow, and we recommended Sell with TP of HK$21.60 in our report in Nov We had expected a good Buy opportunity after 2012 results announcement. Although its share price declined by 6% since our last report, we think it is still not attractive because we think the market may re-evaluate its real cash flow status as well as its business model, and it may deserve a de-rating. Short-sell is not recommended, because the Company will be still in good operation and it is very difficult to predict the timing of de-rating. Future research focus 1) We will have to further analyze Sinopharm s competitors in each provincial market; 2) We will further evaluate our primary thoughts of Sinopharm s roles in the supply chain; 3) We will track the growth slowdown trend of China s drug sales and analyze Sinopharm s industry opportunities. See the last page for disclaimer Page 5 of 8
6 Peers Comparison Company Stock Code Currency Share Price Mkt Cap PER PBR ROE (%) (million) 13F 14F 15F 13F 14F 15F 13F 14F Sinopharm Group Co-H HK HK$ , HK listed health care peers Shanghai Pharmaceuticals-H HK HK$ , Shandong Weigao Gp Medical-H HK HK$ , Sihuan Pharmaceutical Hldgs HK HK$ , Sino Biopharmaceutical HK HK$ , Guangzhou Pharmaceutical-H HK HK$ , China Shineway Pharmaceutica HK HK$ , China Medical System Holding HK HK$ , Microport Scientific Corp HK HK$ , The United Laboratories Inte HK HK$ , Tong Ren Tang Technologies-H HK HK$ , Kingworld Medicines Group HK HK$ n.a n.a Total Simple Average Total Weighted Average Weighted Average Excluding Sinopharm China listed pharmaceutical distributors Jointown Pharmaceutical-A CH RMB , n.a. n.a. n.a. n.a Shanghai Pharmaceuticals-A CH RMB , China National Medicines-A CH RMB ,785 n.a. n.a. n.a China National Accord Medi-A CH RMB , n.a Nanjing Pharmaceutical Co-A CH RMB ,225 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Cachet Pharmaceutical Co-A CH RMB , n.a. n.a. n.a. n.a Zhejiang Zhenyuan Co Ltd-A CH RMB ,282 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. Simple Average Weighted Average US pharmaceutical distributors Mckesson Corp MCK US US$ , Cardinal Health Inc CAH US US$ , Amerisourcebergen Corp ABC US US$ , Simple Average Weighted Average Japanese pharmaceutical distributors Suzuken Co Ltd 9987 JP JPY 3, , Medipal Holdings Corp 7459 JP JPY 1, ,276 n.a Alfresa Holdings Corp 2784 JP JPY 5, , Toho Holdings Co Ltd 8129 JP JPY 2, , Simple Average Weighted Average Source: the Companies, Bloomberg, Guotai Junan International. See the last page for disclaimer Page 6 of 8
7 Financial Statements and Ratios P&L (RMB m) 2011A 2012A 2013F 2014F 2015F Cash Flow (RMB m) 2011A 2012A 2013F 2014F 2015F Revenue 102, , , , ,509 PBT 3,128 4,014 4,763 5,601 6,666 Cost of sales (93,870) (124,844) (150,505) (184,679) (224,948) Ajustment 1,047 1,146 1,828 2,433 3,064 Change in working capital (2,327) (5,217) (6,161) (6,871) (5,954) Gross Profit 8,355 10,943 13,159 16,103 19,561 Income tax paid and others (828) (887) (1,090) (1,281) (1,525) Other income Net cash from operating activities 1,019 4,017 (660) (119) 2,251 Distribution expenses (2,923) (3,730) (4,630) (5,680) (6,917) Administrative expenses (1,965) (2,568) (3,077) (3,755) (4,548) Capex (2,731) (1,282) (1,158) (1,047) (947) Others (99) 0 (194) (515) (515) EBIT 3,636 4,863 6,025 7,371 8,951 Net cash from investing activities (2,830) (2,209) (1,352) (1,562) (1,462) Net finance costs (818) (1,272) (1,537) (2,043) (2,556) Share of profit of associates Issues of shares 2, , Taxiation (725) (934) (1,147) (1,349) (1,605) Net changes of bank accounts 5,674 1,839 4,771 2,654 1,962 Dividends and Interest Paid (1,320) (2,249) (2,584) (3,189) (3,860) PAT 2,403 3,080 3,616 4,252 5,061 Others 240 (4,768) Minority Interest 842 1,106 1,388 1,703 2,074 Net cash from financing activities 7,428 (5,178) 5,409 (489) (1,852) Net Profit 1,561 1,974 2,268 2,598 3,047 Recurring Net Profit 1,359 1,687 1,981 2,311 2,760 Net increase in cash 5,617 (3,369) 3,396 (2,170) (1,063) EPS (RMB) Cash at bgn of Yr 7,475 13,091 11,108 15,215 14,019 Recurring EPS (RMB) Cash at end of Yr 13,092 9,722 14,505 13,045 12,956 Dividend Growth (%) 2011A 2012A 2013F 2014F 2015F DPS (RMB) Revenue Dividend Yield (%) Gross profit EBIT Balance Sheet (RMB m) 2011A 2012A 2013F 2014F 2015F Net Profit PP&E 4,431 5,382 6,459 7,428 8,319 Recurring Net Profit Other noncurrent assets 6,964 8,448 8,636 9,088 9,568 EPS Total noncurrent assets 11,395 13,831 15,095 16,515 17,887 Recurring EPS Cash and cash equivalents 13,091 9,722 14,505 13,045 12,956 Efficiency (as reported) 2011A 2012A 2013F 2014F 2015F Inventories 12,214 13,618 16,783 20,513 24,905 Inventory Days Trade receivables 26,592 37,401 42,996 56,955 65,233 Trade Receivable Days Other current assets 4,336 5,275 6,699 8,517 10,843 Account Payable Days Total current assets 56,233 66,016 80,982 99, ,938 Operating Cycle Days Total assets 67,628 79,847 96, , ,825 Margins and ratios 2011A 2012A 2013F 2014F 2015F Long-term debts 5,182 5,192 9,192 11,030 12,133 Gross Margin (%) Other non-current liabilities 1,766 1,807 5,608 6,393 7,650 Selling Expenses Ratio (%) (2.86) (2.75) (2.75) (2.75) (2.75) Total non-current liabilities 6,948 6,998 14,800 17,422 19,783 Administrative Expenses Ratio (%) (1.92) (1.89) (1.88) (1.87) (1.86) EBIT Margin (%) Short-term debts 8,667 10,888 11,977 13,175 14,492 Net Profit Margin (%) Trade payables 27,054 34,685 39,536 51,032 58,668 Other current liabilities 4,571 4,532 3,455 4,297 5,346 Operating cash flow margin (%) (0.4) (0.1) 0.9 Total current liabilities 40,292 50,105 54,968 68,504 78,507 Interest Coverage (x) Long-term Debts to Total Debts (%) Share capital 2,403 2,403 2,568 2,568 2,568 Debt to Equity Ratio (%) Reserves 13,271 14,676 16,944 18,892 21,178 Net Gearing (%) Net cash Shareholders' equity 15,674 17,078 19,512 21,461 23,746 ROA (%) Minority interests 4,714 5,665 6,798 8,157 9,789 ROE (%) Total equity 20,388 22,743 26,310 29,618 33,535 Valuation 2011A 2012A 2013F 2014F 2015F Total equity and liabilities 67,628 79,847 96, , ,825 P/B (x) BPS (RMB) P/E (x) Source: the Company, Guotai Junan International. See the last page for disclaimer Page 7 of 8
8 Company Rating Definition The Benchmark: Hong Kong Hang Seng Index Time Horizon: 6 to 18 months Rating Definition Buy Relative Performance>15%; or the fundamental outlook of the company or sector is favorable. Accumulate Relative Performance is 5% to 15%; or the fundamental outlook of the company or sector is favorable. Neutral Relative Performance is -5% to 5%; or the fundamental outlook of the company or sector is neutral. Reduce Relative Performance is -5% to -15%; or the fundamental outlook of the company or sector is unfavorable. Sell Relative Performance <-15%; or the fundamental outlook of the company or sector is unfavorable. Sector Rating Definition The Benchmark: Hong Kong Hang Seng Index Time Horizon: 6 to 18 months Rating Definition Outperform Relative Performance>5%; or the fundamental outlook of the sector is favorable. Neutral Relative Performance is -5% to 5%; or the fundamental outlook of the sector is neutral. Underperform Relative Performance<-5%; or the fundamental outlook of the sector is unfavorable. DISCLOSURE OF INTERESTS (1) The Analysts and their associates do not serve as an officer of the issuer mentioned in this Research Report. (2) The Analysts and their associates do not have any financial interests in relation to the issuer mentioned in this Research Report. (3) Except for Shandong Chenming Paper Holdings Limited-H shares (01812) and China City Railway Transportation Technology Holdings Company Limited (08240), Guotai Junan and its group companies do not hold equal to or more than 1% of the market capitalization of the issuer mentioned in this Research Report. (4) Guotai Junan and its group companies have not had investment banking relationships with the issuer mentioned in this Research Report within the preceding 12 months. DISCLAIMER This Research Report does not constitute an invitation or offer to acquire, purchase or subscribe for securities by Guotai Junan Securities (Hong Kong) Limited ("Guotai Junan"). Guotai Junan and its group companies may do business that relates to companies covered in research reports, including investment banking, investment services and etc. (for example, the placing agent, lead manager, sponsor, underwriter or invest proprietarily). Any opinions expressed in this report may differ or be contrary to opinions or investment strategies expressed orally or in written form by sales persons, dealers and other professional executives of Guotai Junan group of companies. Any opinions expressed in this report may differ or be contrary to opinions or investment decisions made by the asset management and investment banking groups of Guotai Junan. Though best effort has been made to ensure the accuracy of the information and data contained in this Research Report, Guotai Junan does not guarantee the accuracy and completeness of the information and data herein. This Research Report may contain some forward-looking estimates and forecasts derived from the assumptions of the future political and economic conditions with inherently unpredictable and mutable situation, so uncertainty may contain. Investors should understand and comprehend the investment objectives and its related risks, and where necessary consult their own financial advisers prior to any investment decision. This Research Report is not directed at, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any jurisdiction where such distribution, publication, availability or use would be contrary to applicable law or regulation or which would subject Guotai Junan and its group companies to any registration or licensing requirement within such jurisdiction Guotai Junan Securities (Hong Kong) Limited. All Rights Reserved. 27/F., Low Block, Grand Millennium Plaza, 181 Queen s Road Central, Hong Kong. Tel.: (852) Fax: (852) Website: See the last page for disclaimer Page 8 of 8
Satisfactory Top-Line; Disappointing Bottom-Line
: Tsingtao Brewery (00168 HK) 公 司 报 告 : 青 岛 啤 酒 (00168 HK) Satisfactory Top-Line; Disappointing Bottom-Line 销 售 增 长 理 想 但 盈 利 能 力 令 人 失 望 Sunny Kwok 郭 日 升 +852 2509 2642 sunny.kwok@gtjas.com.hk GTJA Research
More information1H15 Results Review: Table-1: Chanjet s Income Statement Analysis RMB (Thousand) 1H15 1H14 YoY Comments -Sale of software 170,096 169,278 0.
GTJA Research 国 泰 君 安 研 究 Company Report: Chanjet Information Technology Co. Ltd. (01588 HK) Ricky Lai 黎 柏 坚 公 司 报 告 : 畅 捷 通 (01588 HK) +852 2509 2603 ricky.lai@gtjas.com.hk Stronger Effort to Push Cloud
More informationTough Quarters Ahead, Downgrade to Reduce
: Tsingtao Brewery (00168 HK) Sunny Kwok 郭 日 升 公 司 报 告 : 青 岛 啤 酒 (00168 HK) +852 2509 2642 sunny.kwok@gtjas.com.hk Tough Quarters Ahead, Downgrade to Reduce 未 来 数 季 情 况 更 严 峻, 下 调 至 减 持 GTJA Research 国
More informationCinda International. Hold (Initiation) Target price: HK$1.55. Facing intense competition from Chinese brokers in HK; initiate at Hold
Equity Research Financials Cinda (111 HK) Hold (Initiation) Target price: HK$1.55 Facing intense competition from Chinese brokers in HK; initiate at Hold China Cinda s international business platform Cinda
More informationInvestment Strategy HK STOCK MARKET WRAP
Investment Strategy HK STOCK MARKET WRAP Investment Strategy HK STOCK MARKET WRAP: September 27, 2012 (Thursday) Hong Kong shares moved higher after opening lower. The Hang Seng Index (HSI) opened 40 points
More informationNo Shining Fundamentals, But Cheap Valuation, Accumulate
: Bank of China (03988 HK) Wilson Li 李 伟 公 司 报 告 : 中 国 银 行 (03988 HK) +86 755 23976870 liwei6870@gtjas.com No Shining Fundamentals, But Cheap Valuation, Accumulate 基 本 面 不 靓 丽, 但 估 值 便 宜, 收 集 评 级 GTJA
More informationKingdee (268 HK) Buy (maintained) Target price: HK$3.58. Solidifying leadership in cloud services; maintain Buy but revise TP down to HK$3.
Equity Research Information Technology Aug 2, 21 Kingdee (28 HK) Buy (maintained) Target price: HK$.8 Solidifying leadership in cloud services; maintain Buy but revise TP down to HK$.8 Lower-than-expected
More informationBright Smart (1428 HK)
Equity Research Financials Bright Smart (1428 ) Hold (initiation) Target price: $1.70 Local broker with high ROE; initiate at Hold Local broker with expansion ambition Bright Smart is a securities, commodities
More informationBUY GOLDEN MEDITECH HOLDINGS LIMITED (801 HK) An undervalued healthcare conglomerate. China Medical Devices & Services
BUY Date: 17 November 21 HSI: 23,693.2 Share Price: HK$1.43 12-Mth Target Price: HK$1.9 Upside potential: 32.9% China Medical Devices & Services SHARE INFORMATION Ticker: 81 HK Market Cap HK$2.44bn Issued
More informationAoyuan (3883 HK) Site visit to Guangzhou: Key takeaways
China Real Estates March 10, 2014 Company Report Rating: BUY TP: HK$ 2.20 Ke Share price (HK$) 1.48 Est. share price return 48.6% Est. dividend yield 4.3% Est. total return 52.9% Previous Rating &TP Key
More information2010 2011 2012E 2013E 2014E
11 April 2012 Equity Research Report Company Research Construction Engineering Zhejiang Yasha Decoration (002375) Comments on 2011 annual results Rapid growth in results, while profit quality continued
More informationExhibit 1: Financial summary of First Tractor in 1H12-1H14 1H12 2H12 1H13 2H13 1H14 (% YoY)
Capital Goods Manufacturing ector August 29, 214 Company Report Rating: HOLD TP: HK$ 4.8 H-hare price (HK$) 5.17 Est. share price return (7.16%) Est. dividend yield 1.39% Est. total return (5.77%) First
More information2 September 2015 YOC AG. FIRST BERLIN Equity Research
FIRST ERLIN Equity Research RATING Germany / Advertising Primary exchange: Frankfurt, Xetra Q2/15 Results PRICE TARGET 2.80 loomberg: YOC GR Return Potential 29.6% ISIN: DE0005932735 Risk Rating High SALES
More informationCompany Report. New China Life (1336 HK) Hold Life & Health Insurance Industry 2013E target price: HK$34.30 (from HK$24.
New China Life Company Report New China Life (1336 HK) Hold Life & Health Insurance Industry 2013E target price: HK$34.30 (from HK$24.85 previously) Key data H-share price (HK$) 31.45 Target price (HK$)
More informationInterim P&C Insurance Operation Underperformed Life, Supportive Valuation, Maintain Accumulate
GTJA Research 国 泰 君 安 研 究 Company Report: CPIC (02601 HK) Dayton Wang 王 庆 鲁 公 司 报 告 : 中 国 太 保 (02601 HK) +86 755 2397 6680 wangqinglu010421@gtjas.com Interim P&C Insurance Operation Underperformed Life,
More informationBiostime International (1112 HK) Expensive acquisition brings more challenges; maintain SELL
03/14 04/14 05/14 06/14 07/14 08/14 09/14 10/14 11/14 12/14 01/15 02/15 03/15 04/15 05/15 06/15 07/15 08/15 Biostime International Sep 22, 2015 Company Report Rating: SELL TP: HK$ 12.91 Share price (HK$)
More informationPI Industries. 2QFY16 Result Review HOLD. Custom synthesis restricted 2Q revenue growth ; maintain HOLD. Sector: AGRI
$Com panyname$ Oct-14 Nov-14 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15 2QFY16 Result Review (Wholly owned subsidiary of Bank of Baroda) HOLD PI Industries Ltd. Custom synthesis
More informationPrivate drilling fluid technology service leader
21 March 2012 Equity Research Report Company Research Petroleum & Petrochemical Sichuan Renzhi Oilfield Technology Services (002629) Investment value analysis report Private drilling fluid technology service
More informationSOHO China (410) Buy Nov 20, 2009. Company update. 4 Acquisitions within 6 Months. Samson Man, CFA (852)-2532-1539 samson.man@firstshanghai.com.
SOHO China (410) Company update Buy Nov 20, 2009 4 Acquisitions within 6 Months Purchase Nexus Centre in Beijing. SOHO China announced to acquire Nexus Centre in Beijing. Total GFA is 103,340 sqm. Total
More informationTrxade Group, Inc. (TCQB: TRXD): Record Revenues in Q3
Siddharth Rajeev, B.Tech, MBA, CFA Analyst November 5, 2015 Trxade Group, Inc. (TCQB: TRXD): Record Revenues in Q3 Sector/Industry: E-commerce Market Data (as of November 5, 2015) Current Price $1.15 Fair
More informationFlexituff International Ltd. (FIL)
s $CompanyN ame$ Nov-14 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15 Oct-15 (Wholly owned subsidiary of Bank of Baroda) Q2FY16 Result Review BUY Flexituff International Ltd. (FIL)
More informationLongfor (960 HK) Unrated Real Estate Development Industry
20 Septemper 2012 Equity Focus Key Data Share price (HK$) 11.78 52Wk H/L(HK$) 13.5/6.5 Issued shares (mn) 5,167.3 Market cap (HK$mn) 60,974 30-day avg vol (HK$mn) 137.14 Auditors Deloitte Major shareholder:
More informationHMS Group 3 months 2015 IFRS Results Conference call presentation. 16 June 2015
HMS Group 3 months 2015 IFRS Results Conference call presentation 16 June 2015 Financial results Business & Outlook Appendix Financial Highlights Financial highlights, Rub mn 3m 2015 3m 2014 chg, yoy Revenue
More informationChina Insurance Longer-term Value Emerges
China Insurance Longer-term Value Emerges 2 February 2012 Some improvement in 2012 for the industry after a challenging 2011 2011 a difficult operating environment for life insurers 2011 was a tough year
More informationHCC BUY. Infrastructure January 29, 2016
Jan-15 Mar-15 Apr-15 May-15 Jul-15 Aug-15 Sep-15 Nov-15 Dec-15 Jan-16 India Research Infrastructure January 29, 2016 QUARTERLY REVIEW Bloomberg: IN Reuters: HCNS.BO BUY Better margins drive earnings s
More informationCompany Report. Ping An (2318 HK) Sell Life & Health Insurance Industry 2013E target price: HK$68.46 (from HK$58.04 previously)
Ping An Company Report Ping An (2318 HK) Sell Life & Health Insurance Industry 2013E target price: HK$68.46 (from HK$58.04 previously) Key data H-share price (HK$) 66.95 Target price (HK$) 68.46 Upside
More informationKhambatta Securities Ltd.
Attractive Valuation Strong Buy Sector : Bank Private Target Price : Rs 284 Current Market Price : Rs 230 Market Cap : Rs 1,337 bn 52-week High/Low : Rs 393/216 Daily Avg. Volume : 13.88 mn Shares in issue
More informationCENTRAL SECURITIES CLEARING SYSTEM PLC. CSCS: from West Africa to the rest of the world. Recommendation: BUY
CENTRAL SECURITIES CLEARING SYSTEM PLC NASD EQUITY NIGERIA FINANCIAL SERVICES CSCS: from West Africa to the rest of the world INVESTMENT HIGHLIGHT HALF YEAR 2015: Growing Revenue and Bottom-Line Amidst
More informationConsolidated and Non-Consolidated Financial Statements
May 13, 2016 Consolidated and Non-Consolidated Financial Statements (For the Period from April 1, 2015 to March 31, 2016) 1. Summary of Operating Results (Consolidated) (April 1,
More informationMaruti Suzuki. Source: Company Data; PL Research
Q3 results subdued, Outlook remains good; BUY January 28, 2016 Rohan Korde rohankorde@plindia.com +91 22 66322235 Rating BUY Price Rs4,103 Target Price Rs4,844 Implied Upside 18.1% Sensex 24,470 Nifty
More informationChina Pacific (2601 HK) Unrated Life & health industry
21 August 2012 Equity Focus Key Data H-share price (HK$) 25.20 Target price (HK$) NA Upside potential (%) NA 52Wk H/L(HK$) 31.0 / 19.8 Issued shares: H-shares (mn) 2,313 A-shares (mn) 6,287 H-share mkt
More informationCompany Overview. Financial Performance
Jan/15 Feb/15 Mar/15 Apr/15 May/15 Jun/15 Jul/15 Aug/15 Sep/15 Oct/15 Nov/15 Dec/15 SPS Finquest Ltd CMP: 84.60 January 13, 2015 Stock Details BSE code 538402 BSE ID SPS Face value ( ) 10 No of shares
More informationChina Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2016
China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2016 2Q16 Added 16,744 New Subscribers 2Q16 Revenue Up 12.7% YOY to RMB171.5 Million ($27.0 Million)
More informationLeading enterprise in domestic TFT liquid crystal material market
13 December Research Report Company Research Mid and Small Cap Yantai Valiant Fine Chemicals (002643) New Issuance Pricing Report Leading enterprise in domestic TFT liquid crystal material market Initial
More informationBetter FY13 Results in Life than P&C, Maintain Accumulate
CPIC 中 国 太 保 (2601 HK) Apr-13 May-13 Jul-13 Aug-13 Aug-13 Sep-13 Oct-13 Oct-13 Nov-13 Jan-14 Feb-14 Mar-14 Mar-14 Apr-14 GTJA Research 国 泰 君 安 研 究 Company Report: CPIC (02601 HK) Dayton Wang 王 庆 鲁 公 司
More informationNavin Fluorine International
RESULTS REVIEW 2QFY16 29 OCT 2015 Navin Fluorine International INDUSTRY CHEMICALS CMP (as on 29 Oct 2015) Rs 1,579 Target Price Rs 1,800 Nifty 8,112 Sensex 26,838 KEY STOCK DATA Bloomberg NFIL IN No. of
More informationChina Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year Fiscal 2010
China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year Fiscal 2010 Annual Revenue up 34.4% to RMB 261.5 Million Fiscal 2010 New Subscribers grew 30.5% Conference Call
More informationRAJESH EXPORTS LIMITED GLOBAL PRESENCE IN GOLD AND GOLD PRODUCTS. Earnings Presentation Q2 FY16
RAJESH EXPORTS LIMITED GLOBAL PRESENCE IN GOLD AND GOLD PRODUCTS Earnings Presentation Q2 FY16 Company Overview COMPANY OVERVIEW Rajesh Exports Ltd. (REL) was incorporated in 1989. Currently REL is a leader
More informationGujarat State Petronet Ltd. INR 135
Jan-15 Mar-15 May-15 Jul-15 Sep-15 Nov-15 Jan-16 India Equity Institutional Research Oil & Gas RESULT UPDATE Gujarat State Petronet Ltd. INR 135 Growth in volumes to propel earnings Accumulate Gujarat
More informationStrong operational performance
ABB India Equity Research Engineering & Capital Goods February 8, 2016 Result Update Emkay Your success is our success Strong operational performance CMP Target Price Rs1,134 Rs1,407 ( ) Rating Upside
More informationJSW Energy Ltd. Interest expenses dragged the bottom-line BUY. Jan. 25, 2016
JSW Energy Ltd. Interest expenses dragged the bottom-line JSW Energy Ltd. (JSWEL) reported a mixed set of numbers for Q3 FY16 quarter. The company reported a consolidated total operating income of Rs.
More informationBritannia Industries
Rally in Input costs near term drag, Maintain BUY June 20, 2016 Amnish Aggarwal amnishaggarwal@plindia.com +91 22 66322233 Gaurav Jogani gauravjogani@plindia.com +91 22 66322238 Rating BUY Price Rs2,641
More informationBDI BioEnergy Internat. 14.5 Buy
20/08/13 20/10/13 20/12/13 20/02/14 20/04/14 20/06/14 20/08/14 20/10/14 20/12/14 20/02/15 20/04/15 20/06/15 MATELAN Research Update Note Price as of 20/08/15: 10.80 21 August 2015 Company / Sector Fair
More information22 December 2015 YOC AG. FIRST BERLIN Equity Research
FIRST ERLIN Equity Research RATING Germany / Advertising Primary exchange: Frankfurt, Xetra 9M/15 Results PRICE TARGET 3.00 loomberg: YOC GR Return Potential 53.3% ISIN: DE0005932735 Risk Rating High Q3
More informationSUPREME INDUSTRIES LTD Plastic Products HOLD RETAIL EQUITY RESEARCH
Q2FY16 RESULT UPDATE GEOJIT BNP PARIBAS Research RETAIL EQUITY RESEARCH SUPREME INDUSTRIES LTD Plastic Products BSE CODE:509930 NSE CODE: SUPREMEIND Bloomberg CODE: SIL IN SENSEX: 24,470 HOLD CMP Rs725
More informationSBERBANK GROUP S IFRS RESULTS. March 2015
SBERBANK GROUP S IFRS RESULTS 2014 March 2015 SUMMARY OF PERFORMANCE FOR 2014 STATEMENT OF PROFIT OR LOSS Net profit reached RUB 290.3bn (or RUB 13.45 per ordinary share), compared to RUB 362.0bn (or RUB
More informationGAIL (India) Ltd. INR 346
Feb-15 Apr-15 Jun-15 Aug-15 Oct-15 Dec-15 Feb-16 India Equity Institutional Research Oil & Gas RESULT UPDATE GAIL (India) Ltd. INR 346 Good performance; Near term outlook looks stable BUY GAIL reported
More informationCoal India Ltd. Subdued e-auction realization impacted profitability BUY. Nov. 17, 2015
17-Nov-14 17-Dec-14 17-Jan-15 17-Feb-15 17-Mar-15 17-Apr-15 17-May-15 17-Jun-15 17-Jul-15 17-Aug-15 17-Sep-15 17-Oct-15 Coal India Ltd. Subdued e-auction realization impacted profitability Coal India Ltd.
More informationSK Networks (001740 KS)
Korea Research Earnings review Korea / Industrials 11 January 2013 HOLD Target price Last price (9 Jan 13) KRW9,000 KRW8,590 Upside/downside (%) 4.8 KOSPI 1997.94 Mkt. cap (KRWbn/US$bn) 2,132/2.0 52 week
More informationKotak Mahindra Bank Rs 685
India Equity Institutional Research BANKS RESULT UPDATE Kotak Mahindra Bank Rs 685 Smooth merger; benefits to accrue HOLD KMB s consolidated PAT for Q4FY15 stood at INR 9.5 that primarily on the back of
More informationSundaram Finance. Target price (INR) 452 Momentum in loans sustains, upgrade to Hold
HOLD Target price (INR) 452 Momentum in loans sustains, upgrade to Hold India Equity Research Financials January 30, 2013 Rating The higher than expected growth in the NII was driven by an improvement
More informationMATELAN Research. Intelligent Transportation Systems MEGATRENDS DRIVE MARKET GROWTH FINANCIALS ACCELERATING IVU AND INIT SHOW HIGHEST UPSIDES
MATELAN Research Intelligent Transportation Systems MEGATRENDS DRIVE MARKET GROWTH FINANCIALS ACCELERATING IVU AND INIT SHOW HIGHEST UPSIDES 2/5/12 2/7/12 2/9/12 2/11/12 2/1/13 2/3/13 2/5/13 2/7/13 2/9/13
More informationDiluted net income per share. Six months ended Sep. 30, 2012 0.40 0.39 Six months ended Sep. 30, 2011 (1.09) -
November 9, 2012 Summary of Consolidated Financial Results for the Second Quarter of Fiscal Year Ending March 31, 2013 (Six Months Ended September 30, 2012) [Japanese GAAP] Company name: Japan System Techniques
More informationWeekly A-Share Picks. Nov 9, 2015. A-Share Market. (Note: This is selected translation from the Chinese version of our A-share research notes)
Weekly A-Share Picks Nov 9, 2015 (Note: This is selected translation from the Chinese version of our A-share research notes) A-Share Market (1) Pinggao Electric (600312.SH): Injecting the Group's Main
More informationFSA Note: Summary of Financial Ratio Calculations
FSA Note: Summary of Financial Ratio Calculations This note contains a summary of the more common financial statement ratios. A few points should be noted: Calculations vary in practice; consistency and
More informationMinda Industries Ltd. INR 886
Jan-15 Mar-15 May-15 Jul-15 Sep-15 Nov-15 Jan-16 India Equity Institutional Research Automobiles RESULT UPDATE Minda Industries Ltd. INR 886 Profit boosted by margins ACCUMULATE In Q3FY16, Minda Industries
More informationINVESTOR NEWSLETTER. Contents. 2... Financial Highlights 6... Share Price History 7... About LTLS. November 4 th, 2015
November 4 th, Distributor and Manufacturer - Basic and Specialty Chemicals INVESTOR NEWSLETTER Contents 2... Financial Highlights 6... Share Price History 7... About LTLS PT Lautan Luas Tbk @PTLAUTANLUASTbk
More informationSimplex Infrastructures
2QFY216 Result Update Infrastructure November 17, 215 Simplex Infrastructures Performance Highlights Quarterly highlights - Standalone Y/E March (` cr) 2QFY16 1QFY16 2QFY15 % chg (yoy) % chg (qoq) Net
More informationGlaxoSmithKline Consumer Healthcare
Strong pricing power, Attractive valuations "BUY" February 09, 2016 Amnish Aggarwal amnishaggarwal@plindia.com +91 22 66322233 Gaurav Jogani gauravjogani@plindia.com +91 22 66322238 Rating BUY Price Rs5,837
More informationSalzer Electronics. 2QFY16 Result Review BUY. Steady performance continued; maintain BUY. Sector: Electric Equipment
$CompanyN ame$ Nov-14 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15 Oct-15 Nov-15 2QFY16 Result Review (Wholly owned subsidiary of Bank of Baroda) BUY Salzer Electronics Ltd. Steady
More informationSberbank Group s IFRS Results for 6 Months 2013. August 2013
Sberbank Group s IFRS Results for 6 Months 2013 August 2013 Summary of 6 Months 2013 performance: Income Statement Net profit reached RUB 174.5 bn (or RUB 7.95 per ordinary share), a 0.5% decrease on RUB
More informationMphasis. FY17 could be a year of revenue growth. Source: Company Data; PL Research
FY17 could be a year of revenue growth February 08, 2016 Govind Agarwal govindagarwal@plindia.com +91 22 66322300 Rating Accumulate Price Rs440 Target Price Rs510 Implied Upside 15.9% Sensex 24,617 Nifty
More informationYear-end Dec 2013A 2014E 2015E 2016E Key data. # Priced at market close, 29/09/14
This research is intended for UK institutional investors only and market professionals. It is not intended for retail customers and any retail customer should seek professional, independent advice before
More informationSOHO China [0410.HK] June 19, 2012 BUY. Investment highlights. INITIATE COVERAGE: Buying assets in weak market boosts outlook. Real Estate Sector
Jun11 Aug11 Oct11 Dec11 Feb12 Apr12 SOHO China [0410.HK] INITIATE COVERAGE: Buying assets in weak market boosts outlook Investment highlights Sustained strong office demand in first-tier cities High profit
More information20 May 2015 OpenLimit Holding AG. FIRST BERLIN Equity Research
FIRST ERLIN Equity Research RATING Switzerland / Software Primary exchange: Frankfurt Q1 figures PRICE TARGET 1.10 loomberg: O5H GR Return Potential 37.3% ISIN: CH0022237009 Risk Rating High STRONG SALES
More informationDATRON AG. Investor day supports our positive view. Buy (Buy) 12.50 EUR (12.50 EUR ) BANKHAUS LAMPE // 1 17/09/2015
BANKHAUS LAMPE // 1 DATRON AG Investor day supports our positive view 17/09/2015 Buy (Buy) 12.50 EUR (12.50 EUR ) Close 15/09/2015 9.75 EUR Bloomberg: DAR GY WKN: A0V9LA Sector Engineering Share price
More informationEmpresaria (EMR.L) Empressive finish to the year
26 th January 2015 56 54 52 50 48 46 EMR EMPRESARIA ORD 5P Empresaria (EMR.L) Empressive finish to the year 44 42 40 38 Q1-2014 Q2-2014 Q3-2014 Q4-2014 Price: 43.0p Sourc e: Fides s a 12m High 56.0p 12
More informationFocus on fleet customers SAF-HOLLAND Annual Financial Statements 2013
Focus on fleet customers SAF-HOLLAND Annual Financial Statements 213 Detlef Borghardt, CEO Wilfried Trepels, CFO March 13, 214 Agenda 1 Financials 3 2 Appendix 21 2 Executive Summary 1 2 3 Group sales
More informationBUY. Muted Q3; Brands & Retail story to unfold ARVIND. Target Price: Rs 344. Segmental highlights
05 FEB 2016 Quarterly Update BUY Target Price: Rs 344 Muted Q3; Brands & Retail story to unfold Arvind s Q3 consolidated revenue at Rs 21.6 bn (Rs 20.7 bn in Q3FY15) was marginally below our estimate of
More informationMangalam Cement Weak volumes marred performance
CMP* (Rs) 206 Market Cap. (Rs bn) 5.5 Free Float (%) 72 Shares O/S (mn) 26.7 Mangalam Cement Weak volumes marred performance Mangalam Cement (MCL) delivered a weak performance in 2Q but was marginally
More informationKlöckner & Co SE. Q3 2014 Results
Klöckner & Co SE A Leading Multi Metal Distributor Gisbert Rühl CEO Marcus A. Ketter CFO Results Analysts and Investors Conference November 6, Disclaimer This presentation contains forward-looking statements
More informationprice target of 7.40. We reiterate our Buy rating. Figure 1: Reported figures versus forecasts Source: First Berlin Equity Research, SFC Energy AG
FIRST ERLIN Equity Research RATING Germany / Energy Primary exchange: Frankfurt Q3 figures PRICE TARGET 7.40 loomberg: F3C GR Return Potential 38.1% ISIN: DE0007568578 Risk Rating High PROJECT DELAYS URDEN
More informationChina Property Sector Expecting lower policy risk due to stabilizing home prices
19 September 2012 Equity Focus Key Data Average FY12E PE (x) 5.69 Average FY12E PB (x) 1.14, ABCI Securities HSCIPC performance (%) Absolute Relative* 1-mth 6.3 3.8 3-mth 10.3 4.5 6-mth 6.2 7.7 *Relative
More informationOptimizeRx OPRX. Buy. Platform Potential Continues to Grow $0.87 $4.00. Refer to the last two pages of this report for Disclosures
Nov 14, 2014 Healthcare OptimizeRx Platform Potential Continues to Grow Other OTC OPRX Buy Rating Unchanged Current Price $0.87 Target Price $4.00 Market Capitalization 20.32M Shares Outstanding 23.36M
More informationHOLD. Q4 earnings beat but order backlog flat ABB. Target Price: Rs 1,213. Key drivers
05 FEB 2016 Quarterly Update HOLD Target Price: Rs 1,213 Q4 earnings beat but order backlog flat s Q4CY15revenue at Rs24bnwasin line withour expectation of Rs24bn. EBITDA margin improved 290 bps YoYand
More informationCorporate Profile. Quarterly Highlights. Financial Review. Operation Highlights
Your Testing Quality is Our Commitment. CHROMA ATE INC. 2013 4Q. 2012 Investor Conference Paul Ying, CFO Leo Huang, Chairman & CEO 22 nd February, 2013 1 Disclaimer This presentation contains some forward-looking
More informationJust Dial Ltd Bloomberg Code: JUST IN
Communications - Internet Media Oct 14, 215 Bloomberg Code: JUST IN India Research - Stock Broking India s local search engine, warming up with add-on services Just Dial is now into a platform where people
More informationPEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)
BUY CMP 196.40 Target Price 225.00 STYLAM INDUSTRIES LIMITED Result Update (PARENT BASIS): Q2 FY16 DECEMBER 16 th. 2015 ISIN: INE239C01012 12 th h, 2013 Index Details Stock Data Sector Plastic Products
More informationAccumulate. Exide Industries Ltd(EIL) Automobile Ancillaries RETAIL EQUITY RESEARCH
Q3FY16 RESULT UPDATE GEOJIT BNP PARIBAS Research RETAIL EQUITY RESEARCH Exide Industries Ltd(EIL) Automobile Ancillaries BSE CODE: 500086 NSE CODE: EXIDEIND Bloomberg CODE: EXID IN SENSEX: 23,759 Accumulate
More informationFinancial Analysis Project. Apple Inc.
MBA 606, Managerial Finance Spring 2008 Pfeiffer/Triangle Financial Analysis Project Apple Inc. Prepared by: Radoslav Petrov Course Instructor: Dr. Rosemary E. Minyard Submission Date: 5 May 2008 Petrov,
More informationHOLD. The case of missing sales growth ZYDUS WELLNESS. Target Price: Rs 780. Q3highlights
The case of missing sales growth Zydus Q3 net sales at Rs1.1 bn was up 3% on a like-to-like basis (Q3 15 had Rs 223 mn additional excise duty credit from prior periods), below our estimate of 6%. The company
More informationSOHO CHINA (410.HK) At the Key Phase of Business Transformation. Neutral (Update) HONG KONG PROPERTY COMPANY UPDATE.
SOHO CHINA (410.HK) At the Key Phase of Business Transformation HONG KONG PROPERTY COMPANY UPDATE 26 August 2015 Summary Realized revenue of SOHO China dropped by 92% yoy to RMB393 million while realized
More informationConsolidated Financial Results for the Six Months Ended September 30, 2015 [Japanese GAAP]
Consolidated Financial Results for the Six Months Ended September 30, 2015 [Japanese GAAP] November 6, 2015 Company name: Shibaura Electronics Co., Ltd. Stock exchange listing: Tokyo Stock Exchange Code
More informationAtrium Mortgage Investment Corporation (TSX: AI) Record Year / Shares at Attractive Entry Levels. Sector/Industry: Mortgage Investment Corporation
Siddharth Rajeev, B.Tech, MBA, CFA Analyst February 17, 2016 Atrium Mortgage Investment Corporation (TSX: AI) Record Year / Shares at Attractive Entry Levels Sector/Industry: Mortgage Investment Corporation
More information2009 First Quarter Results Presentation
2009 First Quarter Results Presentation February 17, 2009 Safe Harbor Statement This announcement contains forward-looking statements. These statements are made under the safe harbor provisions of the
More informationExpert System. Strong organic growth with acquisition upside. Growth in annual licensing key to shareholder return
Expert System Strong organic growth with acquisition upside Acquisition and order update Software & comp services Expert Systems has announced encouraging order growth, with US orders up 82% and annual
More informationWuXi PharmaTech Announces Second-Quarter 2014 Results
WuXi PharmaTech Announces Second-Quarter 2014 Results SHANGHAI, August 13, 2014 /Xinhua-PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading research and development services company serving
More informationHow To Profit From Trailer Production
Design the future Second quarter results 215 Detlef Borghardt, CEO Wilfried Trepels, CFO August 6, 215 Agenda 1 Market Development 3 2 Financial information 5 3 Outlook 17 2 Truck and trailer market development
More informationBharat Electronics. Strong margins, improved inflows! Source: Company Data; PL Research
Strong margins, improved inflows! January 28, 2016 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Samir Bendre samirbendre@plindia.com +91 22 66322256 Rating Accumulate Price Rs1,228 Target Price Rs1,353
More informationRatio Analysis CBDC, NB. Presented by ACSBE. February, 2008. Copyright 2007 ACSBE. All Rights Reserved.
Ratio Analysis CBDC, NB February, 2008 Presented by ACSBE Financial Analysis What is Financial Analysis? What Can Financial Ratios Tell? 7 Categories of Financial Ratios Significance of Using Ratios Industry
More informationTYPES OF FINANCIAL RATIOS
TYPES OF FINANCIAL RATIOS In the previous articles we discussed how to invest in the stock market and unit trusts. When investing in the stock market an investor should have a clear understanding about
More informationShare gains with healthy margin uptick; Retain Buy
Colgate-Palmolive India Equity Research Consumers January 23, 2015 Result Update Emkay Your success is our success Share gains with healthy margin uptick; Retain Buy CMP Target Price Rs1,913 Rs1,940 (
More informationCharlene Hamrah (Investment Community) (212) 770-7074 Joe Norton (News Media) (212) 770-3144
Contact: Charlene Hamrah (Investment Community) (212) 770-7074 Joe Norton (News Media) (212) 770-3144 AIG REPORTS FIRST QUARTER 2006 NET INCOME OF $3.20 BILLION NEW YORK, NY, May 10, 2006 American International
More informationChapters 3 and 13 Financial Statement and Cash Flow Analysis
Chapters 3 and 13 Financial Statement and Cash Flow Analysis Balance Sheet Assets Cash Inventory Accounts Receivable Property Plant Equipment Total Assets Liabilities and Shareholder s Equity Accounts
More informationEmirates NBD (ENBD) Strong Buy. Target Price AED10.0. Global Research Investment Update Equity UAE Banking Sector 31 January, 2016
Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15 Oct-15 Nov-15 Dec-15 Jan-16 Global Research Investment Update Equity UAE Banking Sector 31 January, 2016 Market Data Bloomberg Code: Emirates
More informationSAF-HOLLAND Annual Financial Statements 2012. Detlef Borghardt, CEO Wilfried Trepels, CFO. March 14, 2013
SAF-HOLLAND Annual Financial Statements 212 Detlef Borghardt, CEO Wilfried Trepels, CFO March 14, 213 Executive Summary business volume successfully expanded in 212 1 Group sales increased yoy by 3.4%
More informationNordex SE. Analyst Presentation Preliminary Figures FY 2011. Hamburg 28/02/2012
Nordex SE Analyst Presentation Preliminary Figures FY 2011 Hamburg 28/02/2012 Overview Order intake, sales and EBIT before one-off items in line with most recent forecast as of 14 Nov. Guidance 2011p Order
More informationNEUTRAL. Weak FY14, but positive outlook thereafter. June 5 th, 2015
EQUITY RESEARCH FY14 Update June 5 th, 2015 Weak FY14, but positive outlook thereafter NEUTRAL Current Share Price ( ): 3.4 Target Price ( ): 3.8 Enertronica 1Y Performance 120 Weak FY2014 figures, due
More informationThree growth drivers amid high base for growth
14 Aug 2012 Equity Research Report Company Research Electronics Huizhou Speed Wireless Technology (300322) Investment value analysis report Three growth drivers amid high base for growth Investment Highlights
More informationChina Pacific Insurance
Relative Value (%) Equity Research April 25, 2014 China Pacific Insurance All ahead of expectation Results Review Maintain BUY results higher than expectation CPIC reported its handsome results, with net
More information